Communication Trends: How to Prepare for Effective Pharma/Payer Meetings
Manufacturers engage with managed care organizations (MCOs) in a number of ways, from deep conversations regarding clinical indications and brand coverage to general sessions focused on product portfolios and overall business. Although pharma companies have historically engaged with payers in phase III of the drug development lifecycle, pharma/payer meetings are now shifting to earlier in […]
Measuring Message Efficacy: How to Change HCP Brand Perceptions
Pharma companies share product messaging with providers in a myriad of ways, from email campaigns to social media to next-best-action marketing, print and online media, and industry conferences. Despite the rise of omni-channel marketing, in-person meetings are still a crucial means of communicating a brand’s value, efficacy, and competitive differentiators to healthcare professionals (HCPs). Of […]
Asembia Trends: The IRA, High-Cost Drugs and Personalized Care
At the beginning of May, almost 8,000 attendees descended on Las Vegas for Asembia’s AXS24 Summit. While all of the session speakers discussed the future of healthcare in one way or another, MMIT noticed a few common trends about the state of the industry today. If you missed the conference, read on for an overview […]
Understanding Access Barriers in 2024 and Beyond
Navigating the landscape of patient access in the pharma industry has become increasingly complex, extending far beyond traditional channels. The challenges are multifaceted, influenced by evolving policies, innovative payer strategies, and shifts in provider dynamics. Recent market research conducted by MMIT and The Dedham Group, encompassing insights from more than 300 industry stakeholders, sheds light […]
Solving Access Barriers in Biomarker Testing: 5 Tips for Manufacturers
Despite the rapid evolution of personalized medicine, access to genetic testing and next-generation sequencing (NGS) is a challenge—due in no small part to coverage confusion. Physicians struggle to navigate poorly defined testing coverage policies and a fragmentated payer and vendor ecosystem, resulting in delayed care for patients requiring precision therapies. While biomarker testing and NGS […]
What’s New in the Hypertension Market?
The hypertension market is no stranger to new entrants, with therapies ranging from calcium channel blockers and angiotensin II receptor blockers (ARBs) to angiotensin-converting enzyme (ACE) inhibitors and beta blockers. As a mature market, generics are widely available, and many of the more recently approved therapies are combinations of existing agents or different formulations of […]
Focusing on Social Determinants of Health: How to Make an Impact
Consideration of patients’ social determinants of health (SDoH) has been a facet of healthcare delivery in the United States for decades. The CDC defines SDoH as the nonmedical factors that influence a patient’s health outcomes, such as access to care services and medication, housing and food stability, education levels, and employment. During the COVID-19 pandemic, […]
Are We at a Tipping Point for Prescription Digital Therapeutics?
The category of treatments known as ‘digital therapeutics’ is widely misunderstood. Though the term is often conflated with ‘digital health’ tools, such as fitness trackers or meditation apps, digital therapeutics (DTx) are distinguished by their reliance on clinical evidence. DTx products use evidence-based, clinically evaluated software to deliver medical interventions directly to patients to prevent, […]
Payers Troubled by Rise of Alternative Funding Programs
For the past few years, the industry has grappled with the rise of a controversial new pharmacy benefits strategy: alternative funding. Alternative funding programs (AFPs), also known as specialty carve-out programs, are intended to reduce the cost of specialty drugs for both patients and payers. According to proponents, AFPs can help employers improve access while […]
Exploring the Role of AI in Managed Care Organizations
Artificial Intelligence (AI) technology and ChatGPT are disrupting countless industries around the world. For healthcare, the possibilities appear promising, with organizations striving to improve patient outcomes and the overall quality of care. According to Precedence Research, AI in healthcare is expected to surpass $187.95 billion dollars by 2030, growing at a CAGR of 37% during […]